NCT00390143View on ClinicalTrials.gov

Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

Meningococcal vaccine 134612

One intramuscular dose during the primary study

BIOLOGICAL

Mencevax™ ACWY

One subcutaneous dose during the primary study

Trial Locations (1)

8200

GSK Investigational Site, Aarhus N

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00390143 - Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612 | Biotech Hunter | Biotech Hunter